Piper Jaffray GenomeRx Symposium in New York

RNS Number : 1869K
Oxford Biomedica PLC
20 June 2014
 



 

 

 

 

 

 

Oxford BioMedica to participate at the Piper Jaffray GenomeRx Symposium in New York on 23 June 2014

 

 

Oxford, UK - 20 June 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that it will attend Piper Jaffray's GenomeRx Symposium on Monday, June 23, 2014 at The Yale Club, New York.

Oxford BioMedica's Chief Executive Officer, John Dawson, and Kyriacos Mitrophanous PhD, Head of Research, will take part in a panel discussion entitled "Ophthalmology: Seeing The Future of Gene Therapy Clearly" detailing trends for gene therapy in ophthalmology from 12:45 - 1:40 pm (UTC).

 

- Ends -

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications

 

 

Tel: +44 (0)20 3709 5700

 

Note to editors

 

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NRALLFVVRRIIFIS